News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
The smartphone could be a thing of the past if Snap has its way. But at $2,195, it could be a tall order to sell Specs to consumers, even if they were stylish.
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.
Earnings are coming up for Nike as the company tries to engineer a turnaround, but Nike stock continues to plumb 52-week lows.
Trump’s children have been buying and selling stock on his behalf while he’s in office, posing a legal quagmire.
Eli Lilly and Co (NYSE:LLY) shares climbed nearly 6% on Friday after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. The...
In June 2026, Eli Lilly’s Lilly TuneLab announced a collaboration under which Charles River Laboratories will provide standardized nonclinical testing services to AI/ML-enabled biotech companies using the TuneLab drug discovery platform. This collaboration ties Charles River more closely into Lilly’s Catalyze360 ecosystem, potentially deepening its role in data-rich, AI-enhanced preclinical research workflows. We’ll now examine how Charles River’s deeper integration into Lilly’s AI-driven...
US stocks are set for another difficult session on Friday, with the Nasdaq on course for a fifth straight day of losses as investors continue to rotate out of technology shares ahead of the quarter-end. Nasdaq futures were down 1.2% ahead of the opening bell, while S&P 500 and Dow Jones...
Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
Compare global reach to domestic focus as these two funds reveal key differences in cost, risk, and portfolio makeup for healthcare investors.
Amid the debut of positive Phase I data, the biotech will push its lead asset further down the clinical pipeline in endometriosis and pattern hair loss.
Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.
↘️ ON Semiconductor (ON): The chip maker agreed to acquire Synaptics (SYNA) in a roughly $7 billion all-stock transaction, as it seeks to push into physical AI. Shares of ON Semiconductor tumbled 12% premarket, while Synaptics’ stock gained 6%.
Earlier this week, Absci Corporation reported encouraging interim Phase 1 data from its HEADLINE trial of ABS-201 for androgenetic alopecia, showing favorable safety, an estimated half-life of at least 65 days, and progression into a multiple ascending dose stage. On the heels of these results, Absci also completed a roughly US$100.00 million follow-on equity offering backed by Eli Lilly & Company and other institutional investors, underscoring external confidence in the ABS-201 program...
Eli Lilly and Company (NYSE:LLY) is one of the best stocks for beginners to buy now. On June 24, Eli Lilly completed its acquisition of Centessa Pharmaceuticals, aiming to advance the development of orexin receptor 2 agonists. This new class of medicine is designed to treat narcolepsy and other sleep-wake disorders by targeting the brain’s […]
The pharma company, the first to use generative AI to develop a drug that reached clinical trials, is betting longevity treatments will fuel its next phase of growth.
The Nancy Pelosi Stock Tracker account on Wednesday spotlighted Eli Lilly & Co. and Nokia Oyj after President Donald Trump praised the companies’ U.S. investment plans during a rally in Pennsylvania. ‘Keep An Eye’ Trump said Eli Lilly will invest...
Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index gaining 1.7% and the S
Novo Nordisk is no longer the front-runner, but it's not out of the running, either.
Major employers and even governments have begun to address concerns of AI-driven job losses, according to a new report by the Wall Street Journal. Morning Brief Host Julie Hyman is joined by Yahoo Finance Tech Editor Dan Howley and Epistrophy Capital Research chief market strategist Cory Johnson to take a closer look at this headline.
Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.
(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a
A coalition of employers and state governments says it is developing a sweeping strategy to help workers respond to the AI age.
These companies' innovative qualities could help them get ahead of their peers in capitalizing on AI.
Eli Lilly and Company (NYSE:LLY) is included among the 10 Reliable Dividend Stocks to Buy for Long-Term Investors. On June 23, Reuters reported that Eli Lilly and Company (NYSE:LLY) expects to launch its weight-loss pill in Europe and the UK in the second half of 2026 or early 2027. The company plans to target the out-of-pocket […]
In recent days, Abbisko Therapeutics and BioArctic each announced new research and license agreements with Eli Lilly, adding multi-target discovery work worth up to about US$1.90 billion in milestones for Abbisko and up to US$770 million for BioArctic, alongside royalties on any future product sales. These alliances, paired with Lilly’s ongoing advances in obesity, oncology, and neurodegeneration programs, underline how external partnerships are being used to broaden its pipeline beyond its...
(Bloomberg) -- At the Hirslanden clinic overlooking Switzerland’s picturesque Lake Lucerne, prostate cancer patient Jörg Pegelow lies on a reclining chair as a doctor wearing two sets of gloves — one made with lead — injects a saline solution laced with a radioactive drug into a vein in his arm.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapOracle Cut 21,000 Jobs in 12 Months, Says AI Replaced
Absci Corporation said that its drug ABS-201 was well-tolerated and showed a long-lasting presence in the body in a clinical trial.